Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 2/20 | 0.51 |
| ▸ | FAAH | O00519 | 3/20 | 0.40 |
| ▸ | NOD2 | Q9HC29 | 1/20 | 0.39 |
| ▸ | SIRT5 | Q9NXA8 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ESR1 | P03372 | 1/20 | 0.37 |
| ▸ | PGR | P06401 | 1/20 | 0.37 |
| ▸ | HTR1A | P08908 | 1/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.37 |
| ▸ | AR | P10275 | 1/20 | 0.37 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.37 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.37 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.37 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.37 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | GNPAT | O15228 | 1/20 | 0.35 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.35 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8821944 | 0.85 | NOD1 (0.67) | NOD1FAAHALDH1A1MAPTPTGS1 | |
| SCHEMBL9220222 | 0.85 | NOD1 (0.67) | NOD1FAAHALDH1A1MAPTPTGS1 | |
| SCHEMBL8821918 | 0.85 | NOD1 (0.67) | NOD1FAAHALDH1A1MAPTPTGS1 | |
| SCHEMBL11596384 | 0.85 | NOD2 (0.49) | NOD1NOD2SIRT5GNPATPTPN1 | |
| SCHEMBL10778212 | 0.83 | NOD1 (0.59) | NOD1SIRT5ESR1PGRHTR1A | |
| SCHEMBL11120073 | 0.82 | NOD1 (0.46) | NOD1 | |
| SCHEMBL8821938 | 0.82 | NOD1 (0.53) | NOD1FAAHALDH1A1MAPTPTGS1 | |
| SCHEMBL31622131 | 0.81 | NOD1 (0.51) | NOD1FAAHALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22462688 | 0.80 | ALDH1A1 (0.52) | NOD1FAAHALDH1A1MAPTSMN1; SMN2 | |
| SCHEMBL22462686 | 0.80 | ALDH1A1 (0.52) | NOD1FAAHALDH1A1MAPTSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 143 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4487869-A2 | RNA ENCODING A TUMOR ANTIGEN | CureVac SE (DE) | 2025-01-08 | — | — | EP | claimed |
| US-20240091344-A1 | MERS CORONAVIRUS VACCINE | CureVac SE (DE) | 2024-03-21 | — | — | US | claimed |
| EP-3595715-B1 | RNA VACCINE AND IMMUNE CHECKPOINT INHIBITORS FOR COMBINED ANTICANCER THERAPY | CureVac SE (DE) | 2026-05-27 | — | — | EP | disclosed |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | CureVac SE (DE) | 2026-05-21 | — | — | US | disclosed |
| US-20260137769-A1 | NUCLEIC ACID MOLECULES AND USES THEREOF | CureVac SE (DE) | 2026-05-21 | — | — | US | disclosed |
| US-12618060-B2 | Nucleic acid molecules | CureVac SE (DE) | 2026-05-05 | — | — | US | disclosed |
| US-20260102489-A1 | COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY | CureVac SE (DE) | 2026-04-16 | — | — | US | disclosed |
| US-20260090989-A1 | LIPID NANOPARTICLE mRNA VACCINES | CureVac SE (DE) | 2026-04-02 | — | — | US | disclosed |
| US-20260091101-A1 | BUNYAVIRALES VACCINE | CureVac SE (DE) | 2026-04-02 | — | — | US | disclosed |
| US-20260071224-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | CureVac SE (DE) | 2026-03-12 | — | — | US | disclosed |
| US-12569549-B2 | Flavivirus vaccine | CureVac SE (DE) | 2026-03-10 | — | — | US | disclosed |
| US-11345920-B2 | Artificial nucleic acid molecules for improved protein expression | CUREVAC AG (DE) | 2022-05-31 | — | — | US | disclosed |
| US-20220152193-A1 | COMBINATION VACCINE | CUREVAC AG (DE) | 2022-05-19 | — | — | US | disclosed |
| US-20220144877-A1 | RNA SEQUENCE ADAPTATION | CUREVAC AG (DE) | 2022-05-12 | — | — | US | disclosed |
| US-20220136001-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES | CUREVAC AG (DE) | 2022-05-05 | — | — | US | disclosed |
| CN-114381470-A | Artificial nucleic acid molecules | 库瑞瓦格股份公司 | 2022-04-22 | — | — | CN | disclosed |
| US-20220096616-A1 | COMPOSITION FOR TREATING LUNG CANCER, PARTICULARLY OF NON-SMALL LUNG CANCERS (NSCLC) | CUREVAC AG (DE) | 2022-03-31 | — | — | US | disclosed |
| US-11286492-B2 | Artificial nucleic acid molecules for improved protein expression | CUREVAC AG (DE) | 2022-03-29 | — | — | US | disclosed |
| US-20220090092-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | CUREVAC AG (DE) | 2022-03-24 | — | — | US | disclosed |
| CN-106102770-B | Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof | 辉瑞公司 | 2022-03-22 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345920-B2 | Artificial nucleic acid molecules for improved protein expression | NSUN3, CPSF6, CPSF1 | NOD1 2300/4885FAAH 4620/4885NOD2 2417/4885 |
| US-12618060-B2 | Nucleic acid molecules | TP53, MICA, TAP1 | NOD1 3708/4885FAAH 4347/4885NOD2 3551/4885 |
| US-20220152193-A1 | COMBINATION VACCINE | FURIN, HELZ, SF3B5 | NOD1 700/4885FAAH 3711/4885NOD2 827/4885 |
| US-20220090092-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | CPSF6, CPSF1, RNMT | NOD1 2504/4885FAAH 4423/4885NOD2 2668/4885 |
| US-20260102489-A1 | COMBINATION OF VACCINATION AND INHIBITION OF THE PD-1 PATHWAY | PDCD1, PDCD1LG2, CD274 | NOD1 1002/4885FAAH 4165/4885NOD2 1184/4885 |
| US-11286492-B2 | Artificial nucleic acid molecules for improved protein expression | CPSF6, CPSF1, RNMT | NOD1 2504/4885FAAH 4423/4885NOD2 2668/4885 |
| US-20260071224-A1 | ARTIFICIAL NUCLEIC ACID MOLECULES FOR IMPROVED PROTEIN EXPRESSION | RNGTT, RNMT, NSUN3 | NOD1 261/4885FAAH 3910/4885NOD2 598/4885 |
| US-20240091344-A1 | MERS CORONAVIRUS VACCINE | SARS1, RNMT, ACE2 | NOD1 1421/4885FAAH 2291/4885NOD2 1396/4885 |
| US-20260091101-A1 | BUNYAVIRALES VACCINE | RNGTT, RNMT, TIA1 | NOD1 941/4885FAAH 4329/4885NOD2 1499/4885 |
| US-12569549-B2 | Flavivirus vaccine | LNPK, PCTP, CETP | NOD1 668/4885FAAH 1798/4885NOD2 2287/4885 |
| US-20260137768-A1 | ZIKA VIRUS VACCINE | ADAR, RNGTT, UPF1 | NOD1 252/4885FAAH 4149/4885NOD2 1066/4885 |
| US-20260137769-A1 | NUCLEIC ACID MOLECULES AND USES THEREOF | RNMT, RNGTT, NSUN3 | NOD1 63/4885FAAH 4607/4885NOD2 99/4885 |
| US-20260090989-A1 | LIPID NANOPARTICLE mRNA VACCINES | RNMT, NSUN3, SARNP | NOD1 1744/4885FAAH 1529/4885NOD2 2458/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.